The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Enhanced proteolysis of thiopurine S -methyltransferase (TPMT) encoded by mutant alleles in humans ( TPMT ∗ 3 A , TPMT ∗ 2 ): Mechanisms for the genetic polymorphism of TPMT activity
Open accessAbstract
TPMT is a cytosolic enzyme that catalyzes the S -methylation of aromatic and heterocyclic sulfhydryl compounds, including medications such as mercaptopurine and thioguanine. TPMT activity exhibits autosomal codominant genetic polymorphism, and patients inheriting TPMT deficiency are at high risk of potentially fatal hematopoietic toxicity. The most prevalent mutant alleles associated with TPMT deficiency in humans have been cloned and characterized ( TPMT ∗ 2 and TPMT ∗ 3A ), but the mechanisms for loss of catalytic activity have not been elucidated. In the present study, we established that erythrocyte TPMT activity was significantly related to the amount of TPMT protein on Western blots of erythrocytes from patients with TPMT activities of 0.4-23 units/ml pRBC ( r s = 0.99; P < 0.001). Similarly, heterologous expression of wild-type ( TPMT ∗ 1 ) and mutant ( TPMT ∗ 2 and TPMT ∗ 3A ) human cDNAs in yeast and COS-1 cells demonstrated comparable levels of TPMT mRNA but significantly lower TPMT protein with the mutant cDNAs. Rates of protein synthesis were comparable for wild-type and mutant proteins expressed in yeast and with in vitro translation in rabbit reticulocyte lysates. In contrast, pulse–chase experiments revealed significantly shorter degradation half-lives for TPMT ∗ 2 and TPMT ∗ 3A (∼0.25 hr) compared with wild-type TPMT ∗ 1 (18 hr). The degradation of mutant proteins was impaired by ATP depletion and in yeast with mutant proteasomes ( pre-1 strain) but unaffected by the lysosomal inhibitor chloroquine. These studies establish enhanced degradation of TPMT proteins encoded by TPMT ∗ 2 and TPMT ∗ 3A as mechanisms for lower TPMT protein and catalytic activity inherited by the predominant mutant alleles at the human TPMT locus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular cloning: A laboratory manual
Deininger, P. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,682
In Vivo Half-Life of a Protein Is a Function of Its Amino-Terminal Residue
Bachmair, A., Finley, D., & Varshavsky, A. (1986) · Science · doi:10.1126/science.3018930 · Cited by 1,971
Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
Welsh, M. J., & Smith, A. E. (1993) · Cell · doi:10.1016/0092-8674(93)90353-r · Cited by 1,485
Weinshilboum, R. M., & Sladek, S. L. (1980) · PubMed · Cited by 1,195
Yates, C. R., Krynetski, E. Y., Loennechen, T., Fessing, M. Y., Tai, H.-L., Pui, C.-H., Relling, M. V., & Evans, W. E. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-8-199704150-00003 · Cited by 756
Self-citationThe purine path to chemotherapy
Elion, G. B. (1989) · Science · doi:10.1126/science.2649979 · Cited by 687
Lennard, L., Van Loon, J. A., & Weinshilboum, R. M. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.119 · Cited by 593
A program package for simulation and parameter estimation in pharmacokinetic systems
D'argenio, D. Z., & Schumitzky, A. (1979) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(79)90025-4 · Cited by 471
SEGLEN, P. O., GRINDE, B., & SOLHEIM, A. E. (1979) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1979.tb12956.x · Cited by 469
Heinemeyer, W., Kleinschmidt, J. A., Saidowsky, J., Escher, C., & Wolf, D. H. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07982.x · Cited by 418
Cited by
Pui, C.-H., Relling, M. V., & Downing, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra023001 · Cited by 1,185
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Pediatric acute lymphoblastic leukemia
Inaba, H., & Mullighan, C. G. (2020) · Haematologica · doi:10.3324/haematol.2020.247031 · Cited by 696
Weinshilboum, R. M., Otterness, D. M., & Szumlanski, C. L. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.19 · Cited by 549
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
Moriyama, T., Nishii, R., Perez-Andreu, V., Yang, W., Klussmann, F. A., Zhao, X., Lin, T.-N., Hoshitsuki, K., Nersting, J., Kihira, K., et al. (2016) · Nature Genetics · doi:10.1038/ng.3508 · Cited by 477
Self-citationMa, T. Y., Boivin, M. A., Ye, D., Pedram, A., & Said, H. M. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00412.2004 · Cited by 452
Yang, J. J., Landier, W., Yang, W., Liu, C., Hageman, L., Cheng, C., Pei, D., Chen, Y., Crews, K. R., Kornegay, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4671 · Cited by 445
Self-citationMcLeod, H., Krynetski, E., Relling, M., & Evans, W. (2000) · Leukemia · doi:10.1038/sj.leu.2401723 · Cited by 437
Self-citationMultiplex assessment of protein variant abundance by massively parallel sequencing
Matreyek, K. A., Starita, L. M., Stephany, J. J., Martin, B., Chiasson, M. A., Gray, V. E., Kircher, M., Khechaduri, A., Dines, J. N., Hause, R. J., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0122-z · Cited by 436
Self-citationClinical pharmacology and pharmacogenetics of thiopurines
Sahasranaman, S., Howard, D., & Roy, S. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0478-6 · Cited by 405
Evans, W. E., Hon, Y. Y., Bomgaars, L., Coutre, S., Holdsworth, M., Janco, R., Kalwinsky, D., Keller, F., Khatib, Z., Margolin, J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2293 · Cited by 400
Self-citationCaraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy
McLeod, H. L., & Evans, W. E. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.101 · Cited by 331
Self-citationPharmacogenomics: bench to bedside
Weinshilboum, R., & Wang, L. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1497 · Cited by 320
The thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomics
McLeod, H. L., & Siva, C. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.1.89 · Cited by 296
Polymorphism of the thiopurine S-methyltransferase gene in African- Americans
Hon, Y. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.2.371 · Cited by 271
Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms
Fretland, A. J., Leff, M. A., Doll, M. A., & Hein, D. W. (2001) · Pharmacogenetics · doi:10.1097/00008571-200104000-00004 · Cited by 141
Manning, W. C., Zhou, S., Bland, M. P., Escobedo, J. A., & Dwarki, V. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.4-477 · Cited by 140
Metadata
- Authors
- Tai, H.-L., Krynetski, E. Y., Schuetz, E. G., Yanishevski, Y., & Evans, W. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1997-06-10
- Volume
- 94
- Issue
- 12
- Pages
- 6444-6449
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2027950584
- Cited by
- 259
- References
- 26
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.